Haematologica, Vol 92, Issue 6, 834-837 doi:10.3324/haematol.11064
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fabarius, A.
Right arrow Articles by Hochhaus, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fabarius, A.
Right arrow Articles by Hochhaus, A.

Chronic Myeloid Leukemia

Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure

Alice Fabarius, Claudia Haferlach, Martin C. Müller, Philipp Erben, Tanja Lahaye, Michelle Giehl, Oliver Frank, Wolfgang Seifarth, Rüdiger Hehlmann, Andreas Hochhaus

From the III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany (AF, MCM, PE, TL, MG, OF, WS, RH, AH); MLL Münchner Leukämielabor GmbH, München, Germany (CH)

Correspondence: Alice Fabarius, III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg, Wiesbadener Straße 7–11, 68305 Mannheim, Germany. E-mail: alice.fabarius{at}med3.ma.uniheidelberg.de

Clonal cytogenetic aberrations of the Philadelphia chromosome (Ph) positive hematopoiesis have been associated with the natural evolution of chronic myeloid leukemia (CML) to advanced disease. Clonal aberrations of Ph negative metaphases have been described after treatment with interferon or imatinib. This study evaluates the effect of dasatinib on Ph positive clones with additional cytogenetic aberrations and the frequency of novel aberrations in Ph positive and negative metaphases. Seventy-one patients treated with dasatinib after imatinib failure for a median of nine months were evaluated. Novel aberrations within Ph positive and negative clones appeared in six and three patients, respectively.

Key words: chronic myeloid leukemia, cytogenetics, clonal evolution, tyrosine kinase inhibitors, dasatinib.




This article has been cited by other articles:


Home page
 haematolHome page
A. Fabarius, M. Giehl, B. Rebacz, A. Kramer, O. Frank, C. Haferlach, P. Duesberg, R. Hehlmann, W. Seifarth, and A. Hochhaus
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Haematologica, August 1, 2008; 93(8): 1145 - 1154.
[Abstract] [Full Text] [PDF]